Gilde Healthcare Closes Oversubscribed €250 Million ($285 Million) Later Stage and Growth Capital Fund

News provided by

Jun 14, 2016, 02:00 ET

UTRECHT, The Netherlands and CAMBRIDGE, Massachusetts, June 14, 2016 /PRNewswire/ --

New Fund Targets Innovative Scale-up Opportunities in Medtech, Digital Health and Therapeutics

Gilde Healthcare, the European specialist investment firm, today announces the final close of Gilde Healthcare IV, a €250 million ($285 million) later stage and growth capital fund. The new fund, which was oversubscribed, is targeting investments in innovative private scale-up opportunities in medtech, digital health and therapeutics both in Europe and North America.

Gilde Healthcare IV, which closed at its hard cap, is backed by a balanced mix of international investors. Royal Philips (NYSE: PHG, AEX: PHIA) acted as a cornerstone investor, extending the collaboration which started in the previous Gilde Healthcare III fund. Johnson & Johnson Innovation - JJDC, Inc. joined as a new corporate investor in Gilde Healthcare IV. Additional investors include fund-of-funds, sovereign funds such as Danish Growth Fund, endowments, family offices, entrepreneurs and Gilde partners. The European Investment Fund participated in the fund through several of its funding programs including the European Recovery Program and Dutch Venture Initiative II.

Investors have been attracted by Gilde Healthcare's strong track record. In the last three years, Gilde exited 14 portfolio companies across its healthcare funds realizing significant value for its investors. Amongst the companies that were successfully divested over this period are Definiens, the leading provider of image analysis software for digital pathology; Inovalabs, which markets portable oxygen concentrators for patients with respiratory conditions; ProFibrix, which developed a novel topical hemostatic agent to treat fast bleeding wounds; Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design; Santaris, which develops RNA-targeted drugs and Sapiens, a Dutch neuro-modulation company focused on deep brain stimulation for patients suffering from Parkinson's disease.

Pieter van der Meer, Managing Partner, Gilde Healthcare commenting on today's release said, "The healthcare landscape in the US and Europe is changing, driven by the need for more patient centric care and a much sharper focus on value. With our new fund we will continue to pursue our differentiated investment strategy of backing growth and later stage companies developing novel technologies or therapeutics that enable better healthcare outcomes at reduced costs."

Gilde Healthcare's hands-on investment team, which is based on both sides of the Atlantic, actively supports the international growth of its companies. The Gilde Healthcare IV Fund will make equity investments in a single portfolio company of between €15-25 million.

About Gilde Healthcare

Gilde Healthcare is based in Utrecht, The Netherlands and Cambridge, Massachusetts. The firm is organized along two business lines managing separate funds for innovative healthcare technology companies and lower mid-market healthcare services companies.

Gilde has raised over €800 million ($910 million) in dedicated healthcare funds and is actively looking to lead new private investments in medtech, digital health, therapeutics and healthcare services.

For a list of Gilde Healthcare's portfolio companies please visit the website at http://www.gildehealthcare.com

Media Contacts

Gilde Healthcare
Pieter van der Meer
Managing Partner
T +31 30 219 2533
E [email protected]

Citigate Dewe Rogerson
Katja Stout/Sylvie Berrebi
T + 44 020 7282 1052
E [email protected]

Citigate First Financial, the Netherlands
Marieke Heringa - van Kruiningen
T + 31 20 575 40 14
M + 31 6 11 32 75 33
E [email protected]